Why AndroGel (testosterone topical) Causes Acne: The Mechanism Explained

By
Published Updated Last reviewed
Medication safety clinical consultation image for Why AndroGel (testosterone topical) Causes Acne: The Mechanism Explained

Why AndroGel (testosterone topical) Causes Acne: The Mechanism Explained

At a glance

  • Reported incidence: Acne or acneiform eruption occurred in approximately 3 to 6 percent of subjects in the key AndroGel 1% Phase III registration trial, compared with lower rates on placebo, making it one of the most commonly reported dermatologic adverse events in that dataset (FDA prescribing information, AndroGel 1%)
  • Typical onset: Weeks 2 to 8 after initiating or increasing dose; correlates with rising free testosterone and DHT levels
  • Body sites: Face, upper back, and chest, mirroring the distribution of androgen-sensitive pilosebaceous units
  • First-line management: Topical retinoid (tretinoin 0.025 to 0.05%) plus benzoyl peroxide; optimize application site hygiene
  • Escalation triggers: Nodular or cystic lesions, scarring, failure of two topical regimens after 8 to 12 weeks
  • Discontinuation threshold: Severe nodulocystic acne unresponsive to systemic therapy; evaluate benefit-risk of continuing TRT

The Starting Point: What AndroGel Actually Does to Testosterone Levels

AndroGel delivers testosterone transdermally through a hydroalcoholic gel vehicle. After a standard 5 g (50 mg testosterone) daily dose, serum total testosterone rises into the mid-normal male range within 24 hours, and free testosterone follows proportionally. Critically for acne risk, serum DHT also rises, typically to concentrations 30 to 40 percent above baseline, because peripheral tissues, including skin, convert absorbed testosterone aggressively via 5-alpha reductase type 1.

This DHT elevation is not incidental. It is the proximate driver of sebaceous gland hyperactivity. The AndroGel pharmacokinetic data published in the prescribing information show mean DHT-to-testosterone ratios of approximately 0.23 to 0.28 during gel use, higher than ratios seen with intramuscular testosterone esters, which partly explains why acne reports appear consistently across TRT gel products.

Step One: 5-Alpha Reductase in Sebaceous Glands

The sebaceous gland is not a passive bystander receiving androgens from circulation. It is an active steroidogenic tissue. Sebocytes express 5-alpha reductase type 1 at high levels, the same isoenzyme responsible for most peripheral DHT synthesis in skin. When testosterone enters a sebocyte, 5-alpha reductase rapidly converts it to DHT with a roughly 5-fold greater androgen receptor affinity than the parent compound.

This local amplification step means the sebaceous gland experiences a higher effective androgen stimulus than serum testosterone levels alone would predict. A patient with serum testosterone of 600 ng/dL on AndroGel is presenting their sebocytes with a potent intracrine DHT signal that exceeds what simple blood-level monitoring reveals. Studies of sebaceous gland androgen metabolism confirm that skin from acne-prone sites, particularly the face and upper trunk, has higher 5-alpha reductase activity than non-prone sites, which explains the characteristic distribution of TRT-induced acne.

Step Two: Androgen Receptor Activation and Sebocyte Proliferation

DHT binds the intracellular androgen receptor (AR) within sebocytes with high affinity. The DHT-AR complex translocates to the nucleus and acts as a transcription factor, upregulating genes that govern lipid synthesis, cell proliferation, and cell survival. The net result is a larger sebaceous gland producing more sebum per unit time.

Thiboutot and colleagues demonstrated that sebaceous glands from acne-prone facial skin show significantly higher AR expression than glands from non-acne-prone sites, creating a structural reason why some patients develop severe facial acne while others get predominantly truncal involvement. On TRT with AndroGel, this anatomic variability in AR density produces the variable clinical picture prescribers observe: one patient reports only minor truncal comedones while another develops inflamed facial papules within three weeks of initiation.

Step Three: Sebum Composition Shifts Toward Pro-Comedogenic Lipids

Androgen stimulation does not merely increase total sebum volume. It shifts the lipid composition. Zouboulis and colleagues showed that androgen-stimulated sebocytes increase the proportion of squalene and wax esters in sebum while reducing the relative proportion of linoleic acid. Squalene, when oxidized by reactive oxygen species at the follicular surface, becomes comedogenic. A lower follicular linoleic acid concentration impairs the barrier function of the follicular epithelium, promoting hyperkeratosis.

This biochemical shift explains why AndroGel-induced acne is not simply an oily skin problem. It is a structural change in follicular biology. Patients who manage AndroGel acne with oil-control cleansers alone typically achieve incomplete control because they are addressing surface sebum volume without correcting the upstream lipid composition problem.

Step Four: Follicular Hyperkeratosis and Microcomedone Formation

The follicular infundibulum, the neck of the hair follicle where it opens onto the skin surface, is also androgen-sensitive. Androgen receptor signaling in follicular keratinocytes promotes abnormal cornification: keratinocytes in the infundibulum proliferate faster and shed less efficiently, forming a plug of corneocytes and sebum. This is the microcomedone, the universal precursor lesion in all acne subtypes.

On AndroGel, rising DHT levels accelerate microcomedone formation within the first few weeks, often before visible lesions appear. This is clinically important: patients who start a topical retinoid at TRT initiation, rather than waiting for visible acne, can theoretically interrupt this step before the cascade produces inflammatory lesions. Tretinoin and adapalene both act on retinoic acid receptors in keratinocytes to normalize follicular cornification, directly countering the hyperkeratotic effect of DHT. The AAD acne management guidelines endorse topical retinoids as first-line for comedonal and papulopustular acne, a recommendation that transfers logically to androgen-induced presentations.

Step Five: Cutibacterium acnes Colonization and Inflammation

The sebum-filled, hyperkeratotic follicle is an anaerobic, lipid-rich environment that favors proliferation of Cutibacterium acnes (formerly Propionibacterium acnes). C. acnes produces lipases that hydrolyze sebum triglycerides into free fatty acids, further irritating the follicular wall. Its cell-surface components activate toll-like receptor 2 on follicular keratinocytes and adjacent immune cells, triggering release of interleukin-1 beta, tumor necrosis factor-alpha, and matrix metalloproteinases.

This innate immune response converts the silent microcomedone into the clinically visible papule, pustule, or nodule. Patients on AndroGel who have pre-existing acne-prone skin, meaning higher baseline sebaceous gland density, higher AR expression, or a history of adolescent acne, are entering TRT with a sebum and C. acnes burden already present. The androgen stimulus from AndroGel amplifies a primed system rather than initiating acne de novo, which is why their responses are often faster and more severe than in acne-naive patients.

Why Topical Testosterone Application Site Matters

AndroGel is typically applied to shoulders, upper arms, or abdomen. The gel vehicle penetrates skin and delivers testosterone into the dermal capillary bed for systemic absorption. However, local sebaceous gland concentrations at the application site are transiently higher than at distant sites. Wiehle and colleagues documented that DHT concentrations in skin biopsies from application sites exceed those at non-application sites during the first several hours after gel use.

This creates a practical point: patients who apply AndroGel to the upper chest or apply it without allowing full drying before contact with their own face may be delivering a higher-than-intended local androgen signal to acne-prone sites. Rotating application sites and ensuring full drying before clothing contact reduces, though does not eliminate, this local amplification effect.

Dose Dependency: More Testosterone Means More Acne Risk

The prescribing information for AndroGel 1.62% notes that acne adverse event rates are dose-related across the 20.25 mg, 40.5 mg, and 81 mg daily dose cohorts. This dose-response relationship directly reflects the 5-alpha reductase conversion relationship: higher serum testosterone produces higher serum and intrasebocyte DHT, driving greater sebaceous gland stimulation.

For prescribers, this means that dose reduction, when clinically permissible within the goal of maintaining therapeutic testosterone levels, is a legitimate first step before escalating to systemic acne therapy. A patient with moderate inflammatory acne on 81 mg daily who achieves adequate testosterone levels on 40.5 mg daily may see significant acne improvement from the dose change alone. Checking serum DHT alongside total testosterone provides a more complete picture: a DHT above 650 ng/dL signals excessive 5-alpha reductase activity and correlates with higher acne risk per Endocrine Society TRT guidelines.

Practical Management Aligned With the Mechanism

Understanding the mechanism translates directly into a rational treatment ladder:

Step 1, address sebum quality: A non-comedogenic cleanser twice daily reduces surface squalene oxidation. Niacinamide 4 to 5% topically reduces sebum excretion rate within 4 to 8 weeks by a mechanism independent of androgen blockade, per Draelos and colleagues.

Step 2, normalize follicular keratinization: Tretinoin 0.025% or adapalene 0.1% nightly targets the hyperkeratosis step directly. Expect a 6 to 8 week induction period before full effect. Adapalene 0.1% gel is well tolerated on back and shoulder skin.

Step 3, reduce C. acnes burden: Benzoyl peroxide 2.5 to 5% applied in the morning limits bacterial overgrowth and reduces resistance risk compared with topical antibiotics used alone, consistent with AAD guideline recommendations.

Step 4, systemic options: Moderate to severe inflammatory acne unresponsive to two topical agents after 8 to 12 weeks warrants doxycycline 100 mg twice daily for 8 to 12 weeks, per standard guidelines. Isotretinoin is reserved for nodulocystic or scarring disease; coordinate with a dermatologist.

Step 5, reconsider TRT parameters: If acne persists despite steps 1 to 4, check serum DHT. Dose reduction, if testosterone goals allow, or a formulation switch to transdermal patches, which produce lower DHT-to-testosterone ratios, may resolve treatment-resistant cases without discontinuing TRT entirely.

Frequently asked questions

›How quickly does acne appear after starting AndroGel?
›Will my acne go away on its own if I stay on AndroGel?
›Is the acne from testosterone gel different from regular teenage acne?
›Does AndroGel cause more acne than testosterone injections?
›Can I use a 5-alpha reductase inhibitor like finasteride to prevent AndroGel acne?
›Why is my acne on my back and shoulders rather than my face?
›Does washing the application site after a few hours reduce acne?
›Can women or transgender men on AndroGel get acne from the same mechanism?
›Should I stop AndroGel if I get acne?
›Is the acne a sign that my testosterone dose is too high?

References